QDENGA Dengue Vaccine India: First Approved Dengue Vaccine, Key Facts

QDENGA dengue vaccine India: Learn about India’s first approved dengue vaccine, CDSCO approval, Takeda, age eligibility, doses, four serotypes and 2027 availability.

India Approves Its First Dengue Vaccine

India has reached an important milestone in public health with the approval of QDENGA, the country’s first dengue vaccine. The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, granted marketing authorisation for QDENGA in July 2026 for individuals aged 4 to 60 years. The vaccine is manufactured by Takeda and is designed to protect against all four dengue virus serotypes.

What Is QDENGA?

QDENGA, also known as TAK-003, is a live attenuated tetravalent dengue vaccine. The term tetravalent refers to its ability to target the four recognised dengue virus serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. This broad coverage is significant because different dengue serotypes circulate in India and other dengue-endemic regions.

Developer and Vaccine Technology

QDENGA was developed by Takeda, a Japanese pharmaceutical company. It uses recombinant DNA technology and is based on a dengue virus type-2 backbone, with genetic components corresponding to other serotypes. The vaccine is produced using Vero cells and is supplied as a freeze-dried preparation that is reconstituted before administration.

Age Eligibility and Dosing Schedule

Under the Indian approval, QDENGA is indicated for people between 4 and 60 years of age. The recommended vaccination schedule consists of two 0.5 ml doses, administered three months apart. An important feature of the approval is that pre-vaccination dengue infection testing is not required for administering the vaccine under the approved indication.

WHO Prequalification and Global Status

QDENGA has already achieved international regulatory milestones. The vaccine received World Health Organization prequalification in 2024 and has been approved in numerous countries. According to the Government of India, the vaccine had been approved in 42 countries at the time of India’s July 2026 authorisation, while subsequent company information reported approvals in 43 countries including India. More than 24 million doses had been distributed globally according to the July government release.

QDENGA’s Availability in India

Although India has approved QDENGA, approval does not mean that the vaccine immediately becomes available throughout the country. Takeda and Dr. Reddy’s Laboratories entered into an exclusive agreement in September 2026 for promotion and distribution of QDENGA in India’s private market for paediatric and adult vaccination. Subject to the completion of applicable regulatory and commercial procedures, private-market availability is anticipated in the first half of 2027.

Public Health Significance of the Vaccine

Dengue is a major mosquito-borne viral disease in India, transmitted primarily by Aedes mosquitoes. The approval of QDENGA provides an additional preventive tool alongside mosquito-control measures, disease surveillance, early diagnosis and appropriate clinical management. The Government of India has specifically described vaccination as complementary to existing dengue prevention and control efforts.

QDENGA and India’s Indigenous Vaccine Efforts

QDENGA’s approval should also be understood alongside India’s own efforts to develop dengue vaccines. The Indian Council of Medical Research has supported the development of DengiAll, an indigenous tetravalent dengue vaccine. Its Phase III clinical trial began in August 2024 across 19 sites in 18 states and Union Territories, involving more than 10,000 healthy adult volunteers.

Why Dengue Prevention Remains Important

Dengue prevention is particularly challenging because the virus has four major serotypes and is transmitted by mosquitoes that can thrive in urban and semi-urban environments. Consequently, vaccination alone cannot eliminate dengue transmission. Removing mosquito breeding sites, improving surveillance, preventing mosquito bites and ensuring timely medical care remain important components of dengue control.

Why This News Is Important

A Major Public Health Milestone

The approval of QDENGA represents a significant development in India’s approach to dengue prevention because it is the first dengue vaccine to receive approval in India. For government-exam aspirants, this is an important current-affairs topic connecting public health, biotechnology, pharmaceutical regulation and infectious diseases.

Relevance to India’s Disease Burden

Dengue continues to pose a public-health challenge in India, where multiple dengue virus serotypes circulate. The availability of an approved vaccine adds another potential layer of prevention to existing strategies such as vector control, surveillance, early diagnosis and case management.

Importance for Science and Biotechnology

QDENGA is also relevant from a biotechnology perspective because it is a live attenuated tetravalent vaccine developed using recombinant DNA technology. Questions in examinations may test concepts such as vaccine type, dengue serotypes, vaccine developer and the regulatory authority responsible for approval in India.

Importance for Healthcare Access

The planned private-market launch is expected in the first half of 2027, subject to completion of applicable processes. Dr. Reddy’s Laboratories is responsible for exclusive promotion and distribution in the private market under its agreement with Takeda. The vaccine’s price and any future inclusion in public immunisation programmes had not been announced in the cited September 2026 reports.

Exam Relevance

For UPSC, State PSC, SSC, banking, railways, defence and other competitive examinations, aspirants should remember the key facts: QDENGA is developed by Takeda, approved by CDSCO, covers four dengue serotypes, is indicated in India for ages 4–60, and follows a two-dose schedule three months apart. These facts connect current affairs with static subjects such as health, biotechnology and government regulation.

Historical Context: Background of Dengue Vaccination

Dengue as a Global Health Challenge

Dengue is a mosquito-borne viral disease caused by dengue viruses belonging to the Flavivirus genus. The disease is transmitted mainly through infected Aedes mosquitoes. The existence of four major dengue virus serotypes—DENV-1, DENV-2, DENV-3 and DENV-4—has made vaccine development scientifically complex.

Development of QDENGA

Takeda developed QDENGA as a tetravalent dengue vaccine intended to provide protection against all four dengue serotypes. Its development included clinical studies in dengue-endemic and non-endemic regions. India’s regulatory assessment also included a Phase III safety and immunogenicity study involving the Indian population aged 4 to 60 years.

WHO Prequalification in 2024

An important international milestone came in 2024, when QDENGA received WHO prequalification. WHO prequalification is an important quality-assurance mechanism that assesses vaccines and other health products against established standards, facilitating their consideration for use by international procurement agencies and national programmes.

India’s 2026 Regulatory Approval

In July 2026, CDSCO granted marketing authorisation for QDENGA, making it the first dengue vaccine approved in India. The approval followed scientific evaluation of its quality, safety and efficacy under India’s regulatory framework, including the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945.

India’s Indigenous Vaccine Research

India has simultaneously pursued domestic dengue-vaccine research. ICMR’s DengiAll programme reached Phase III clinical trials in August 2024, with trials conducted across multiple states and Union Territories. This illustrates India’s broader effort to develop indigenous solutions for diseases of major public-health importance.

Key Takeaways from QDENGA Dengue Vaccine

FAQs: QDENGA Dengue Vaccine

1. What is QDENGA?

QDENGA, also known as TAK-003, is a live attenuated tetravalent dengue vaccine developed by Takeda. It is designed to protect against all four dengue virus serotypes: DENV-1, DENV-2, DENV-3 and DENV-4.

2. Why is QDENGA important for India?

QDENGA is the first dengue vaccine approved in India. The Central Drugs Standard Control Organisation (CDSCO) granted its marketing authorisation in July 2026.

3. Which organisation approved QDENGA in India?

The Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation for QDENGA in India. CDSCO functions under the Ministry of Health and Family Welfare.

4. Who developed QDENGA?

QDENGA was developed by Takeda, the Japan-based pharmaceutical company. The vaccine is manufactured by Takeda GmbH, Germany, for the Indian authorisation described by the Government of India.

5. Which age group is eligible for QDENGA in India?

The Indian approval covers individuals aged 4 to 60 years.

6. How many doses of QDENGA are required?

The approved vaccination schedule consists of two doses of 0.5 ml each, administered three months apart.

7. What does tetravalent mean in the context of QDENGA?

Tetravalent means that the vaccine is designed to provide protection against four dengue virus serotypes: DENV-1, DENV-2, DENV-3 and DENV-4.

8. Does QDENGA require pre-vaccination dengue screening?

The approved indication does not require pre-vaccination screening for previous dengue infection. Recent reporting also states that QDENGA can be administered irrespective of prior dengue infection.

9. What type of vaccine is QDENGA?

QDENGA is a recombinant live attenuated tetravalent vaccine. It uses a dengue virus type-2 backbone with genetic components corresponding to the other serotypes.

10. When is QDENGA expected to become available in India’s private market?

Following an agreement between Takeda and Dr. Reddy’s Laboratories, QDENGA is anticipated to become available in India’s private market in the first half of 2027, subject to applicable regulatory and other processes.

Some Important Current Affairs Links